CAMBRIDGE, MA, USA I July 14, 2015 I Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced recent progress in its PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company’s R&D pipeline, including its TIM-3 antibody program.
Enumeral has identified antibodies that appear to bind to PD-1 in a manner different from that of currently marketed anti-PD1 antibodies, while retaining activity in cell-based assays. The Company has isolated more than 300 sequences of PD-1 binding antibodies from primary B cells in its PD-1 program. The Company’s bioinformatics analysis of sequences indicates that these antibodies are diverse, falling into 26 distinct clades, or families, that bind to PD-1. Enumeral has advanced six lead clones into pre-clinical characterization, four of which are undergoing humanization. The Company anticipates that the humanization process will be completed by the end of the third quarter of 2015, which will enable initiation of cell line development for IND-enabling studies.
“We believe that such differentiated antibodies might elicit desirable cellular immune responses among subsets of tumor infiltrating lymphocytes (TILs) that differ from those observed with competitor antibodies against the same target,” said Cokey Nguyen, Ph.D., Enumeral’s Vice President of Research and Development. “This identification of differentiated binding to a validated target is an exciting discovery, and we are now in the process of more fully characterizing these antibodies using our proprietary human biopsy-based immuno-profiling platform. Our longer-term goal is to determine if these antibodies have utility in treating different types of tumors than those treated by currently marketed drugs, as well as whether such antibodies may increase initial response rates among patients who fail in other therapies.”
In Enumeral’s TIM-3 program, the Company has isolated 180 screening hits and has sequenced 88 TIM-3 binding antibodies to date, and its screening efforts are ongoing. Enumeral’s bioinformatics analysis indicates desirable diversity, with the antibodies falling into 17 unique clades that bind to TIM-3. Enumeral plans to apply its unique approach to cellular immune response profiling to further understand the utility of these different antibodies for modulation of different TILs. The Company believes antibodies that block TIM-3 may potentiate anti-cancer immune responses, either as a monotherapy or in combination with other therapies, including other immune checkpoint-targeted drugs. The Company currently anticipates nominating lead clones by the end of the third quarter 2015, and beginning the humanization process by the end of this year.
Enumeral also noted that it is engaged in ongoing antibody screening in its LAG-3, OX40, and VISTA programs. Using human biopsy samples, the Company intends to validate antibody blocking effects against these targets, and then assess potential monotherapy or combination therapy regimens using our proprietary antibodies.
“We are very excited by the recent developments in our internal pipeline, particularly with respect to our PD-1 program,” said Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer of Enumeral. “We are currently pursuing the therapeutic implications of our potentially different classes of antibodies using our ex vivo human immuno-oncology profiling platform, and we look forward to reporting on our continued progress in the months ahead.”
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases. The Company is building a pipeline focused on next-generation checkpoint modulators, with initial targets including PD-1, TIM-3, LAG-3, OX40, and VISTA. In developing these agents, Enumeral’s researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells, providing key insights for candidate selection and validation. For more information on Enumeral, please visit www.enumeral.com.
SOURCE: Enumeral Pharma
Post Views: 132
CAMBRIDGE, MA, USA I July 14, 2015 I Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced recent progress in its PD-1 antibody program. Enumeral also provided an update on the progress of additional programs in the Company’s R&D pipeline, including its TIM-3 antibody program.
Enumeral has identified antibodies that appear to bind to PD-1 in a manner different from that of currently marketed anti-PD1 antibodies, while retaining activity in cell-based assays. The Company has isolated more than 300 sequences of PD-1 binding antibodies from primary B cells in its PD-1 program. The Company’s bioinformatics analysis of sequences indicates that these antibodies are diverse, falling into 26 distinct clades, or families, that bind to PD-1. Enumeral has advanced six lead clones into pre-clinical characterization, four of which are undergoing humanization. The Company anticipates that the humanization process will be completed by the end of the third quarter of 2015, which will enable initiation of cell line development for IND-enabling studies.
“We believe that such differentiated antibodies might elicit desirable cellular immune responses among subsets of tumor infiltrating lymphocytes (TILs) that differ from those observed with competitor antibodies against the same target,” said Cokey Nguyen, Ph.D., Enumeral’s Vice President of Research and Development. “This identification of differentiated binding to a validated target is an exciting discovery, and we are now in the process of more fully characterizing these antibodies using our proprietary human biopsy-based immuno-profiling platform. Our longer-term goal is to determine if these antibodies have utility in treating different types of tumors than those treated by currently marketed drugs, as well as whether such antibodies may increase initial response rates among patients who fail in other therapies.”
In Enumeral’s TIM-3 program, the Company has isolated 180 screening hits and has sequenced 88 TIM-3 binding antibodies to date, and its screening efforts are ongoing. Enumeral’s bioinformatics analysis indicates desirable diversity, with the antibodies falling into 17 unique clades that bind to TIM-3. Enumeral plans to apply its unique approach to cellular immune response profiling to further understand the utility of these different antibodies for modulation of different TILs. The Company believes antibodies that block TIM-3 may potentiate anti-cancer immune responses, either as a monotherapy or in combination with other therapies, including other immune checkpoint-targeted drugs. The Company currently anticipates nominating lead clones by the end of the third quarter 2015, and beginning the humanization process by the end of this year.
Enumeral also noted that it is engaged in ongoing antibody screening in its LAG-3, OX40, and VISTA programs. Using human biopsy samples, the Company intends to validate antibody blocking effects against these targets, and then assess potential monotherapy or combination therapy regimens using our proprietary antibodies.
“We are very excited by the recent developments in our internal pipeline, particularly with respect to our PD-1 program,” said Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer of Enumeral. “We are currently pursuing the therapeutic implications of our potentially different classes of antibodies using our ex vivo human immuno-oncology profiling platform, and we look forward to reporting on our continued progress in the months ahead.”
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel antibody immunotherapies that help the immune system fight cancer and other diseases. The Company is building a pipeline focused on next-generation checkpoint modulators, with initial targets including PD-1, TIM-3, LAG-3, OX40, and VISTA. In developing these agents, Enumeral’s researchers apply a proprietary immune profiling technology platform that measures functioning of the human immune system at the level of individual cells, providing key insights for candidate selection and validation. For more information on Enumeral, please visit www.enumeral.com.
SOURCE: Enumeral Pharma
Post Views: 132
